The aim of the present study was to systematically compare outcomes between antibiotic
classes in treating outpatient community-acquired pneumonia, with regard to antibacterials …

Objective: This study presents a cost-minimisation analysis of moxifloxacin compared to
combination treatment with levofloxacin and ceftriaxone in patients hospitalised with …

Current guidelines recommend the use of ceftriaxone and sulbactam-ampicillin for the initial
treatment of community-acquired pneumonia (CAP). However, there are no clear data on …

Importance The clinical benefit of adding a macrolide to a β-lactam for empirical treatment of
moderately severe community-acquired pneumonia remains controversial. Objective To test …

Objective: Some studies suggest better outcomes with macrolide therapy for critically ill
patients with community-acquired pneumonia. To further explore this, we performed a …

Background Lower respiratory tract infection (LRTI) is the third leading cause of death
worldwide and the first leading cause of death in low‐income countries. Community …

Objective The main aim of this network meta-analysis is to identify the empiric antibiotic (Em-
ATB) with the highest probability of being the best (HPBB) in terms of (1) cure rate and (2) …

New respiratory fluoroquinolones (FQs), such as levofloxacin, offer many improved qualities
over older agents, such as ciprofloxacin. These include retaining excellent Gram-negative …

It is unclear whether in the treatment of community‐acquired pneumonia (CAP) beta‐lactam
plus macrolide antibiotics lead to better survival than beta‐lactam alone. We report a …

No comparative effectiveness study has been conducted for the following 3 antibiotics:
respiratory fluoroquinolone, β-lactam, and β-lactam+ advanced macrolide. To gain insights …